🚀 Poloniex New Listing $TRN @t3rn_io✅ Deposit open on July 18th, 08:00 (UTC)✅ Full trading enable on July 18th, 12:00 (UTC)Details: https://t.co/kPJGfGrJ5i https://t.co/LIDTk08dDR ...

🚀 Poloniex New Listing $TRN @T3RN_official✅ Deposit open on July 18th, 08:00 (UTC)✅ Full trading enable on July 18th, 12:00 (UTC)Details: https://t.co/kPJGfGrJ5i https://t.co/rdbbQdeJo4 ...

Pipeline and Milestones - Aprea Therapeutics' WEE1 inhibitor (APR-1051) ACESOT-1051 Phase 1 study expects safety/efficacy data in H2 2025 and complete dose escalation in H1 2026 [7, 43] - Aprea Therapeutics' ATR inhibitor (ATRN-119) ABOYA-119 Phase 1/2a study expects safety/efficacy data in H2 2025 and Recommended Phase 2 Dose (RP2D) in H1 2026 [8, 68] - Six patients in the ATRN-119 dose escalation cohorts achieved stable disease, with three patients (50%) in the 550mg BID cohort demonstrating measurable tumor shrinkage of 7%, 14%, and 21% [53] APR-1051 (WEE1 Inhibitor) - APR-1051 is a potent WEE1 inhibitor with high selectivity, showing >150-fold, >50-fold, and >600-fold difference in IC50 compared to PLK1, PLK2, and PLK3 inhibition, respectively [31] - Clinical data cutoff on March 4, 2025, for APR-1051 (N=9) showed treatment-related adverse events, including alanine aminotransferase increased (2 patients), aspartate aminotransferase increased (2 patients), and lymphocyte count decreased (1 patient) [26] ATRN-119 (ATR Inhibitor) - ATRN-119 exhibits near-dose proportional exposure following oral administration, with AUC 0-24hr ranging from 180 ng*h/mL at 50mg to 6899 ng*h/mL at 550mg [55] - Clinical data cutoff on May 1, 2025, for ATRN-119 (N=32) showed treatment-related adverse events, including nausea (13 patients), diarrhea (12 patients), and fatigue (10 patients) [57] - ATRN-119 is the first and only macrocyclic ATR inhibitor, potentially offering increased selectivity and improved tolerability compared to first-generation acyclic structures [59, 66] Financials and Capitalization - As of March 31, 2025, Aprea Therapeutics had approximately $19.3 million in cash and equivalents [73] - Aprea Therapeutics has 5,531,373 common stock, 2,701,864 warrants, 782,243 options, and 30,607 restricted stock units outstanding as of May 14, 2025, resulting in 9,061,683 fully diluted equivalents [73]

编辑丨王多鱼 排版丨水成文 结直肠癌 （Colorectal Cancer，CRC） 是全世界范围内发病人数第三的癌症 （近 200 万人，仅次于 肺癌 和 乳腺癌 ） ，死亡人数第二的癌症 （近 100 万 人，仅次于 肺癌 ） ， 结直肠癌在早期通常无症状，因此，诊断出来时往往已是晚期，因此需要手术、放疗和化疗等积极治疗。 然而，这些治疗方法也有局限性——手术复发率高，放 疗可引起严重并发症，化疗常导致耐药，约 50% 的患者会出现复发。此外，近 30 年来，50 岁以下的年轻人群中结直肠癌的发病率一直在上升。这使得结直肠 癌成为重大的公共卫生和社会经济问题。 该研究发现， TRMT6 介导的 tRNA 的 N1-甲基腺苷 （m 1 A） 修饰，作为组蛋白合成的 翻译检查点 ，促进结直肠癌发生发展。这一发现为深入理解结直肠癌 进程的分子机制提供了新视角。 在这项最新研究中，研究团队发现， 转运RNA （tRNA） 的 N1-甲基腺苷 （m 1 A） 甲基转移酶 TRMT6 在人类结直肠癌 （CRC） 组织中表达上调，并且 TRMT6 的高表达与结直肠癌患者的不良预后相关。 研究团队利用原位、转移和条件性基 ...

Core Insights - Aprea Therapeutics has initiated dosing of the first patient with HPV+ head and neck squamous cell carcinoma in the ACESOT-1051 clinical trial evaluating APR-1051, marking a significant milestone in the study [1][4] - The ACESOT-1051 trial aims to assess the safety and efficacy of APR-1051, a WEE1 inhibitor, in patients with advanced solid tumors, particularly those with specific gene alterations [3][5] Company Overview - Aprea Therapeutics is focused on developing innovative cancer treatments that target specific vulnerabilities in cancer cells while minimizing harm to healthy cells [1][7] - The company's lead product, APR-1051, is a small molecule designed to address tolerability issues associated with the WEE1 class of inhibitors [3][7] Clinical Trial Details - The ACESOT-1051 trial is a Phase 1 study that will evaluate APR-1051's safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in advanced solid tumors [5][6] - The trial consists of two parts: Part 1 focuses on dose escalation with an expected enrollment of up to 39 patients, while Part 2 aims for dose optimization with up to 40 patients [5][6] HPV+ Cancer Context - HPV+ head and neck squamous cell carcinoma is characterized by defects in the DNA damage response pathway, making it a potential target for WEE1 inhibition [2] - Approximately 70% of the 20,000 annual cases of oropharyngeal squamous cell carcinoma in the U.S. are linked to HPV [2]